2022 article

TLR-activated mesenchymal stromal cell therapy and antibiotics to treat multi-drug resistant Staphylococcal septic arthritis in an equine model

Pezzanite, L. M., Chow, L., Phillips, J., Griffenhagen, G. M., Moore, A. R., Schaer, T. P., … Goodrich, L. R. (2022, September 23). ANNALS OF TRANSLATIONAL MEDICINE.

By: L. Pezzanite, L. Chow, J. Phillips, G. Griffenhagen, A. Moore, T. Schaer, J. Engiles, N. Werpy ...

author keywords: Antibiotic resistance; infectious arthritis; mesenchymal stromal cell (MSC)
Source: Web Of Science
Added: November 28, 2022

Background: Rapid development of antibiotic resistance necessitates advancement of novel therapeutic strategies to treat infection. Mesenchymal stromal cells (MSC) possess antimicrobial and immunomodulatory properties, mediated through antimicrobial peptide secretion and recruitment of innate immune cells including neutrophils and monocytes. TLR-3 activation of human, canine and equine MSC has been shown to enhance bacterial killing and clearance in vitro, in rodent Staphylococcal biofilm infection models and dogs with spontaneous multi-drug-resistant infections. The objective of this study was to determine if intra-articular (IA) TLR-3-activated MSC with antibiotics improved clinical parameters and reduced bacterial counts and inflammatory cytokine concentrations in synovial fluid (SF) of horses with induced septic arthritis.